Such that basically 80% of patients through 6 months did not require any rescue aflibercept therapy.
#OTX 300 TRIAL#
What we found with the phase 1 clinical trial was that there is, in patients who have controlled neovascular AMD at baseline, OTX-TKI was able to continue to control it. And this was over many months after intravitreal administration. And what we found in those data was that there's consistently over 100 fold increase over the minimum inhibitory concentration necessary to control the deleterious effects of angiogenesis including vascular leakage and the other effects of CMV formation in non-human primates and also in rabbit model. I'll start with that first, because that kind of is the predicate for moving forward with human studies. And we also shared some previously unreported data, evaluating pharmacokinetic data in 2 different animal models. This is an interim analysis for this phase 1 prospective, randomized and controlled study. So we shared our data up through 10 months. I had the opportunity to share our data on OTX-TKI in a phase 1 study looking at patients with neovascular AMD. I'm here in New Orleans at the ARVO 2023 annual meeting. Video transcriptĮditor’s note: Transcript lightly edited for clarity. Ophthalmology Times® talked with Andrew Moshfeghi, MD, MBA, about OTX-TKI in a phase 1 study looking at patients with neovascular AMD this year's ARVO meeting.
0 kommentar(er)
